Pacira BioSciences(NASDAQ) PCRX

Pacira BioSciences, Inc. helps doctors treat pain without addictive narcotics. It makes injections providing relief after surgical procedures. These products help patients recover safely without using opioids.

Managing Pain Without Opioids

• EXPAREL: Long-acting local anesthetic injected during surgery to provide pain relief for several days after a procedure.
• ZILRETTA: Extended-release corticosteroid injection designed to manage knee pain for patients suffering from osteoarthritis.
• PCRX-201: Experimental gene therapy currently in testing that aims to provide long-term joint pain relief with one injection.
• PCRX-2002: Investigational long-acting pain medication being developed for use following surgical operations.

Strategic Moves and New Partners

• Divested the iovera device business to Zimmer in July 2026 for an upfront payment of $70.0 million.
• Entered a partnership with LG Chem in January 2026 to expand the availability of EXPAREL in Asian-Pacific markets.
• Expanded patient access in July 2026 through a new reimbursement agreement with UnitedHealthcare for outpatient settings.
• Completed a manufacturing upgrade in July 2026 to produce its lead gene therapy candidate at a commercial scale.

Innovation in Drug Delivery

Pacira uses a proprietary delivery technology that wraps medicine in tiny particles to release it slowly over several days. This allows a single injection to provide long-lasting relief directly at the site of surgery or injury.

A Closer Look at the Finances

• Total revenues reached $192.4 million in the three-month period ended June 30, 2026, which was a 6% increase year over year.
• EXPAREL net product sales grew 3% year over year to $147.8 million during the three-month period ended June 30, 2026.
• ZILRETTA net product sales rose 4% year over year to $32.6 million in the three-month period ended June 30, 2026.
• The company held $251.0 million in cash, cash equivalents, and available-for-sale investments as of June 30, 2026.

The Evolving Business Model

Pacira has shifted its focus toward becoming a biopharmaceutical company centered on non-opioid pain therapies and genetic medicines. Its recent sale of medical device assets and investment in gene therapy manufacturing support this long-term strategy.